Drug Trial Radar · NCT06558188
Combined Anabolic Therapy
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Feb 3, 2025
Primary completion
Nov 2, 2027
Study completion Nov 19, 2027
Sponsor
- Lead sponsor
- Massachusetts General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- First posted
- Aug 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.
Conditions
- Osteoporosis, Postmenopausal
- Osteoporosis
Interventions
RomosozumabDrug
romosozumab 210 milligrams monthly
TeriparatideDrug
teriparatide 20 micrograms daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Lumbar spine areal bone mineral densityTime frame: Month 0 to 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.